These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 25939220)

  • 1. [Initial management of venous thromboembolism].
    Mismetti P; Bertoletti L
    Rev Prat; 2015 Feb; 65(2):193-8. PubMed ID: 25939220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing pulmonary embolism from presentation to extended treatment.
    Cohen AT; Dobromirski M; Gurwith MM
    Thromb Res; 2014 Feb; 133(2):139-48. PubMed ID: 24182642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
    Prandoni P
    Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New anticoagulants in the management of venous thromboembolism in women.
    Piovella F; Irina Iosub D
    Thromb Res; 2015 Feb; 135 Suppl 1():S5-7. PubMed ID: 25903537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
    Patel AA; Ogden K; Mody SH; Bookhart B
    J Med Econ; 2015 May; 18(5):323-32. PubMed ID: 25557176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns of venous thromboembolism in a real-world population: the Q-VTE study cohort.
    Tagalakis V; Patenaude V; Kahn SR; Suissa S
    Thromb Res; 2014 Oct; 134(4):795-802. PubMed ID: 25135794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease.
    Voukalis C; Lip GY; Shantsila E
    Expert Opin Pharmacother; 2016 Oct; 17(15):2033-47. PubMed ID: 27667112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical management of rivaroxaban for the treatment of venous thromboembolism.
    Imberti D; Benedetti R
    Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update in the treatment of venous thromboembolism.
    Garcia DA; Spyropoulos AC
    Semin Respir Crit Care Med; 2008 Feb; 29(1):40-6. PubMed ID: 18302085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous thromboembolism: contemporary diagnostic and therapeutic aspects.
    Bounameaux H; Righini M; Perrier A
    Vasa; 2008 Aug; 37(3):211-26. PubMed ID: 18690588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban.
    Dault R; Vanasse A; Blais L; Perreault S; Farand P; Le Templier G; Beauchesne MF
    Clin Appl Thromb Hemost; 2016 Nov; 22(8):765-771. PubMed ID: 26467323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT; Dobromirski M
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of New Oral Anticoagulants in the Treatment of Venous Thromboembolism and Thrombotic Prophylaxis.
    Akin M; Schäfer A; Akin I; Widder J; Brehm M
    Cardiovasc Hematol Disord Drug Targets; 2015; 15(2):92-6. PubMed ID: 26666324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial treatment of venous thromboembolism.
    McRae SJ; Ginsberg JS
    Circulation; 2004 Aug; 110(9 Suppl 1):I3-9. PubMed ID: 15339875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
    Fanola CL
    Vasc Health Risk Manag; 2015; 11():271-82. PubMed ID: 26064057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Algorithmic Approach to Management of Venous Thromboembolism.
    Dhakal P; Gundabolu K; Bhatt VR
    Clin Appl Thromb Hemost; 2017 Sep; 23(6):511-517. PubMed ID: 27268941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study.
    Prandoni P
    Eur J Haematol; 2012 Oct; 89(4):281-7. PubMed ID: 22834998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating patients with cancer and acute venous thromboembolism.
    Donadini MP; Squizzato A; Ageno W
    Expert Opin Pharmacother; 2016; 17(4):535-43. PubMed ID: 26606049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.